After obtaining a degree in Natural Sciences (Genetics) from Cambridge University and a PhD in molecular biology from Warwick University, Philip joined Dehns in 1992. He is a qualified UK and European patent attorney, and a partner in Dehns’ Life Sciences Group.
Type of clients and client work
Philip’s work is largely with start-ups, small/medium size companies and universities with inventions in the pharmaceutical or biotechnological fields. He has over 25 years’ experience in dealing with the issues which are important to such entities, such as the financial constraints of start-ups, the need to develop IP strategies for a company’s products and the pressures upon academics to publish their work.
Philip’s work involves writing and filing patent applications, and getting them granted for my clients all around the world. He has particular expertise in obtaining European patents (including dealing with EPO Opposition and Appeal procedures) and US patents. He also provides advice on IP landscapes and Freedom to Operate (FTO) advice on competitors’ patents.
Using his background in molecular biology, Philip deals with patents and formulates IP strategies in all pharmaceutical and biotechnological fields, including recombinant DNA and protein products, antibodies, biosimilars, transgenic plants and animals, bioinformatics, stem cells, biofuels, diagnostics assays, therapeutic treatments, virology and vaccines.
He has particular expertise in antibody patents having worked one day/week as an “in-house” patent attorney with a therapeutic antibody company for 2 years. During that time, he helped to develop their world-wide IP strategy for protecting their newly-developed targets, monoclonals and ADCs.
Philip currently works one day/month as an “in-house” patent attorney with another of his clients, a biofuels company which uses advanced fermentation technology to produce biobutanol. His close relationship with them allows him to understand their commercial strategy better, and to ensure that the patent applications that he writes satisfy the requirements of that commercial strategy.
More recently, he has been involved in the patenting of a number of CRISPR/Cas9-based inventions and recombinant vaccines.
Qualifications and Memberships
- European Patent Attorney, 1997
- UK Chartered Patent Attorney, 2001
- Fellow of the Chartered Institute of Patent Attorneys (CIPA)
- CIPA Life Sciences Committee Member, 2001-2016
- Member of the European Patent Institute (epi)
- Basic Litigation Skills Course, 2017
MA, Natural Sciences (Genetics), University of Cambridge (UK), 1988
PhD, Molecular Biology, Warwick University (UK), 1992
Certificate in Intellectual Property Law, Queen Mary College, London, 1993
Philip was highlighted as a "genetics guru” in the IAM Patent 1000: The World's Leading Patent Professionals 2018 ranking tables. He was noted for understanding "the commercial realities of running a business as well as how to decode elaborate legal concepts for laypeople”. Philip has also been listed in the 2018 edition of Who's Who Legal: Patents.
Philip was a member of the Life Sciences Committee of the UK Chartered Institute of Patent Attorneys (CIPA) from 2001-2016. His work on that Committee included reviewing proposed changes to UK and EPO patent legislation, and keeping UK patent attorneys updated on changes to biotech patent law and practice worldwide.
In the last 15 years, he has spoken at over 150 European and UK conferences (and on BBC Radio) about the patenting of biotechnological inventions, and has published several papers in Nature Biotechnology and Nature Reviews, including the following:
Webber, PM, “Does CRISPR-Cas open new possibilities for patents or present a moral maze?” Nature Biotechnology (2014), 32:4, 331-333
Webber, PM, “Protecting your inventions: The patent system" Nature Reviews Drug Discovery (2003), 2:10, 823-830
Webber, PM, "Patent primer: Priority applications" Nature Reviews Drug Discovery (2005), 4, 877
Webber, PM, “Patenting of micro-organisms” Nature Reviews Drug Discovery (2006), 5, 13
Webber, PM, “Patenting antibodies” Nature Reviews Drug Discovery (2006), 5, 97
Philip delivered a lecture at the University of Oxford on the basics of intellectual property, different types of IP and why it is important for any business. Click HERE to view it.
“Patenting Biotech Inventions” (Biotechnology for Non-Biotechnologists conference, 26th-28th April 2017, Nice, France).
“CRISPR IP: Update on the Patent Wars” (Genome Editing/CRISPR 2017 meeting, 4th April 2017, Wolfson College, Oxford, UK).
“How to protect your ideas” (Oxford Science Innovation Union seminar, 21st February 2017, Department of Biochemistry, Oxford).